Drug Database
Back to search

Belgium· BE-AMP-SAM401457-00

Ilaris 150 mg

A canakinumab product containing canakinumab, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.

ATC L04AC08

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedIlaris 150 mgATCL04AC08REGISTER NO.BE-AMP-SAM401457-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about canakinumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Canakinumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search canakinumab products by name

Canakinumab · ATC L04AC08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Canakinumab
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
L04AC08
ATC class
Canakinumab
Defined daily dose
2.7 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    7722507

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

374 interactions on record for canakinumab.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check canakinumab against other medicinesHow interaction checks work

Canakinumab · interactions on record

374 records

  • 30 severe
  • 337 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Canakinumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canakinumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ilaris
  • Liechtenstein · Ilaris
  • Norway · Ilaris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2a475d04-3667-4ca4-879c-70463c7dc323
GET /v1/drugs/2a475d04-3667-4ca4-879c-70463c7dc323?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Ilaris 150 mg",
  "name_fr": "Ilaris 150 mg",
  "name_nl": "Ilaris 150 mg",
  "amp_code": "SAM401457-00",
  "strengths": [
    "150.0000",
    "150.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Canakinumab"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Canakinumab",
  "authorisation_numbers": [
    "EU/1/09/564/003"
  ]
}
API referenceMCP serverPlans

See everything about canakinumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console